Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment

Journal of Investigative Dermatology

Volumn 135, Issue 8, 2015, Pages 2040-2048

  Gray, Elin S ^a   Reid, Anna L ^a   Bowyer, Samantha ^b   Calapre, Leslie ^a   Siew, Kelvin ^b   Pearce, Robert ^a   Cowell, Lester ^c   Frank, Markus H ^a,d   Millward, Michael ^b,e   Ziman, Mel ^a,f  

^a EDITH COWAN UNIVERSITY   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c Level 1 Melanoma Skin Cancer Clinic   (Australia)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER B5; B RAF KINASE; CD146 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; DABRAFENIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IPILIMUMAB; MELANOMA SSOCIATED CHONDROITIN SULPHATE PROTEOGLYCAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NIVOLUMAB; PEMBROLIZUMAB; PROTEOCHONDROITIN SULFATE; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; ABCB5 PROTEIN, HUMAN; CSPG4 PROTEIN, HUMAN; INDOLE DERIVATIVE; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; NERVE GROWTH FACTOR RECEPTOR; NERVE PROTEIN; NGFR PROTEIN, HUMAN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SULFONAMIDE; TNFRSF11A PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL HETEROGENEITY; CELL SUBPOPULATION; CIRCULATING TUMOR CELL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SENSITIVITY; EVALUATION STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA CELL; MELANOMA CELL LINE; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; CANCER STAGING; CELL CULTURE; DRUG EFFECTS; DRUG THERAPY; IMMUNOTHERAPY; MELANOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN NEOPLASMS; TUMOR CELL LINE; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD146; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELLS, CULTURED; CHONDROITIN SULFATE PROTEOGLYCANS; DRUG THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; INDOLES; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; NERVE TISSUE PROTEINS; P-GLYCOPROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, NERVE GROWTH FACTOR; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84937633811     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.127     Document Type: Article

References (28)

1. Baccelli I, Schneeweiss A, Riethdorf S et al. (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31:539-44
2. Blagosklonny MV (2005) Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle 4:1693-8
3. Boiko AD, Razorenova OV, van de Rijn M et al. (2010) Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466:133-7
4. Chartrain M, Riond J, Stennevin A et al. (2012) Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. PLoS One 7:e36762
5. de Bono JS, Scher HI, Montgomery RB et al. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302-9
6. Fang D, Nguyen TK, Leishear K et al. (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65:9328-37
7. Faye RS, Aamdal S, Hoifodt HK et al. (2004) Immunomagnetic detection and clinical significance of micrometastatic tumor cells in malignant melanoma patients. Clin Cancer Res 10:4134-9
8. Freeman JB, Gray ES, Millward M et al. (2012) Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. J Transl Med 10:192
9. Grichnik JM, Burch JA, Schulteis RD et al. (2006) Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol 126:142-53
10. Homet B, Ribas A (2014) New drug targets in metastatic melanoma. J Pathol 232:134-41
11. Hou JM, Krebs MG, Lancashire L et al. (2012) Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 30: 525-32
12. Khoja L, Lorigan P, Zhou C et al. (2013) Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J Invest Dermatol 133:1582-90
13. Konieczkowski DJ, Johannessen CM, Abudayyeh O et al. (2014) A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov 4:816-27
14. Krebs MG, Sloane R, Priest L et al. (2011) Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 29:1556-63
15. Kupas V, Weishaupt C, Siepmann D et al. (2011) RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells. J Invest Dermatol 131:944-55
16. Lucci A, Hall CS, Lodhi AK et al. (2012) Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 13:688-95
17. Ma J, Lin JY, Alloo A et al. (2010) Isolation of tumorigenic circulating melanoma cells. Biochem Biophys Res Commun 402:711-7
18. Monzani E, Facchetti F, Galmozzi E et al. (2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43:935-46
19. Palafox M, Ferrer I, Pellegrini P et al. (2012) RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res 72: 2879-88
20. Pilati P, Mocellin S, Bertazza L et al. (2012) Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis. Ann Surg Oncol 19:402-8
21. Rao C, Bui T, Connelly M et al. (2011) Circulating melanoma cells and survival in metastatic melanoma. Int J Oncol 38:755-60
22. Reid AL, Freeman JB, Millward M et al. (2014) Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clin Biochem. in press
23. Roesch A, Mueller AM, Stempfl T et al. (2008) RBP2-H1/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells. Int J Cancer 122:1047-57
24. Roesch A, Vultur A, Bogeski I et al. (2013) Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell 23:811-25
25. Schatton T, Murphy GF, Frank NY et al. (2008) Identification of cells initiating human melanomas. Nature 451:345-9
26. Sun YF, Xu Y, Yang XR et al. (2013) Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepato-cellular carcinoma after curative resection. Hepatology 57:1458-68
27. Ulmer A, Schmidt-Kittler O, Fischer J et al. (2004) Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin Cancer Res 10:531-7
28. Wilson BJ, Saab KR, Ma J et al. (2014) ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. Cancer Res 74: 4196-207